Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $47.87 USD
Change Today +0.53 / 1.12%
Volume 877.7K
SGEN On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $52.33
52 Week Low
01/16/15 - $30.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEATTLE GENETICS INC (SGEN)

seattle genetics inc (SGEN) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGEN) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 55 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage programs, including SGN-CD19A for CD19A-positive hematologic malignancies; SGN-CD33A in CD33-positive acute myeloid leukemia; SGN-LIV1A in LIV-1-positive breast cancer; ASG-22ME for the treatment of Nectin-4-positive solid tumors; ASG-15ME for treatment of SLITRK6-positive bladder cancer; and SEA-CD40, a non-fucosylated antibody utilizing a novel immuno-oncology technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

657 Employees
Last Reported Date: 02/27/15
Founded in 1998

seattle genetics inc (SGEN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $759.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.1K
Chief Operating Officer
Total Annual Compensation: $472.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $448.0K
Executive Vice President of Process Sciences ...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2014.

seattle genetics inc (SGEN) Key Developments

Seattle Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Sales Guidance for the Year of 2015

Seattle Genetics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $77,096,000 against $68,308,000 a year ago. Loss before income taxes was $47,563,000 against $17,643,000 a year ago. Net loss was $47,502,000 or $0.38 per basic and diluted share against $17,590,000 or $0.14 per basic and diluted share a year ago. For the six months, the company reported total revenues of $159,253,000 against $136,579,000 a year ago. Loss before income taxes was $69,306,000 against $34,014,000 a year ago. Net loss was $69,192,000 or $0.55 per basic and diluted share against $33,891,000 or $0.28 per basic and diluted share a year ago. The company anticipates that 2015 revenues from ADCETRIS net product sales in the U.S. and Canada will be slightly higher than previously anticipated, and are now expected to be in the range of $210 million to $220 million.

SFC Energy AG Announces Addition of Fisheries Supply as Marine Distributor of EFOY COMFORT Fuel Cells in the Western United States

SFC Energy AG announced that it will partner with Seattle, WA, USA, to serve as a new marine distributor for the popular EFOY COMFORT fuel cells in the United States. Fisheries Supply Company has been a specialist in marine products since 1928, serving recreational boaters as well as boat dealers, builders and yards, chandleries and commercial fishermen across the Pacific Northwest, Alaska and beyond. The company is a leading distributor of marine products in the Pacific Northwest. Fisheries Supply will sell the full range of EFOY COMFORT fuel cells and fuel cartridges to customers along the West Coast of the United States, one of the large recreational boat markets on the globe.

Seattle Genetics, Inc. Initiates Clinical Trial of ADCETRIS in Systemic Lupus Erythematosus

Seattle Genetics, Inc. announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus). Lupus is a chronic autoimmune disease in which the body’s own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on activated lymphocytes that are thought to play a key role in the development of autoimmune diseases, including lupus. The trial is designed to assess the safety and activity of ADCETRIS in adult patients with lupus. ADCETRIS is currently not approved for the treatment of lupus. The study is a phase 2 randomized, double-blind, placebo-controlled dose-escalation clinical trial. The primary objective is evaluation of the safety of ADCETRIS in adults with active lupus. In addition, the trial will evaluate the activity and pharmacokinetics of ADCETRIS in lupus. ADCETRIS will be administered every three weeks and approximately 40 patients will be enrolled at multiple centers in the United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $47.87 USD +0.53

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr639.50 DKK +1.50
Insys Therapeutics Inc $44.92 USD +0.90
Medivation Inc $105.33 USD +8.36
MorphoSys AG €72.90 EUR +0.70
Pfizer Ltd/India 2,176 INR +53.85
View Industry Companies

Industry Analysis


Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.3x
Price/Book 33.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at